Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models

by Jinsong Hu, Els Van Valckenborgh, Eline Menu, Elke De Bruyne, Karin Vanderkerken
Published 2012-11-01

An Improved Harvest and in Vitro Expansion Protocol for Murine Bone Marrow-Derived Mesenchymal Stem Cells

by Song Xu, Ann De Becker, Ben Van Camp, Karin Vanderkerken, Ivan Van Riet
Published 2010-01-01

Identification of the immune checkpoint signature of multiple myeloma using mass cytometry‐based single‐cell analysis

by Jinheng Wang, Yongjiang Zheng, Chenggong Tu, Hui Zhang, Karin Vanderkerken, Eline Menu, Jinbao Liu
Published 2020-01-01

Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy

by Yanmeng Wang, Niels Vandewalle, Kim De Veirman, Karin Vanderkerken, Eline Menu, Elke De Bruyne
Published 2024-06-01

Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma

by Elke De Bruyne, Karin Vanderkerken, Ivan Van Riet, Ken Maes, Eline Menu, Els Van Valckenborgh
Published 2013-04-01

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells

by Liesbeth Bieghs, Jo Caers, Elke De Bruyne, Els Van Valckenborgh, Fiona Higginbotham, Karin Vanderkerken, Eline Menu
Published 2010-01-01

Mithramycin exerts an anti-myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factors.

by Eléonore Otjacques, Marilène Binsfeld, Natacha Rocks, Silvia Blacher, Karin Vanderkerken, Agnès Noel, Yves Beguin, Didier Cataldo, Jo Caers
Published 2013-01-01

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?

by Catharina Muylaert, Lien Ann Van Hemelrijck, Anke Maes, Kim De Veirman, Eline Menu, Karin Vanderkerken, Elke De Bruyne
Published 2022-08-01

The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma

by Philip Vlummens, Philip Vlummens, Kim De Veirman, Eline Menu, Elke De Bruyne, Fritz Offner, Karin Vanderkerken, Ken Maes
Published 2019-08-01

Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma

by Inge Oudaert, Arne Van der Vreken, Anke Maes, Elke De Bruyne, Kim De Veirman, Karin Vanderkerken, Eline Menu
Published 2022-09-01

Histone deacetylase inhibitors in multiple myeloma

by Sarah Deleu, Eline Menu, Els Van Valckenborgh, Ben Van Camp, Joanna Fraczek, Isabelle Vande Broek, Vera Rogiers, Karin Vanderkerken
Published 2009-06-01

The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response

by Eva De Smedt, Hui Lui, Hui Lui, Ken Maes, Kim De Veirman, Eline Menu, Karin Vanderkerken, Elke De Bruyne
Published 2018-12-01

Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects

by Lien De Beck, Sarah Melhaoui, Kim De Veirman, Eline Menu, Elke De Bruyne, Karin Vanderkerken, Karine Breckpot, Ken Maes
Published 2018-10-01

The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers

by Rong Fan, Nathan De Beule, Anke Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Ken Maes, Karine Breckpot, Kim De Veirman
Published 2022-10-01

AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma

by Siyang Yan, Niels Vandewalle, Nathan De Beule, Sylvia Faict, Ken Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Kim De Veirman
Published 2019-11-01

Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions

by Emma Verheye, Jesús Bravo Melgar, Sofie Deschoemaeker, Geert Raes, Anke Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Damya Laoui, Kim De Veirman
Published 2022-01-01

Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential

by Ken Maes, Ken Maes, Anna Mondino, Juan José Lasarte, Xabier Agirre, Xabier Agirre, Karin Vanderkerken, Felipe Prosper, Felipe Prosper, Felipe Prosper, Karine Breckpot
Published 2021-03-01

Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients.

by Song Xu, Gaia Cecilia Santini, Kim De Veirman, Isabelle Vande Broek, Xavier Leleu, Ann De Becker, Ben Van Camp, Karin Vanderkerken, Ivan Van Riet
Published 2013-01-01

S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma

by Yanmeng Wang, Catharina Muylaert, Arne Wyns, Philip Vlummens, Kim De Veirman, Karin Vanderkerken, Esther Zaal, Celia Berkers, Jérome Moreaux, Elke De Bruyne, Eline Menu
Published 2023-07-01

Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition

by Mérédis Favreau, Koen Venken, Sylvia Faict, Ken Maes, Kim De Veirman, Elke De Bruyne, Xavier Leleu, Louis Boon, Dirk Elewaut, Karin Vanderkerken, Eline Menu
Published 2017-07-01